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Xanthoma disseminatum (XD) is a rare normolipemic histiocytic disorder of non-Langerhans cell origin characterized by
erythematous to tan/brown papules in ﬂexor surfaces. Considered a generally benign, chronic disease of unknown etiology, XD
typically aﬀects the skin, mucous membranes, and less commonly, other organs. To date, there has been no typical or consistent
inheritance pattern described, nor has it ever been considered as a component of any known syndrome. We describe, for the ﬁrst
time, two cases of XD in a pair of blind and deaf twin brothers.
1.Introduction
Xanthoma disseminatum (XD) is a disorder of non-
Langerhans cell origin that is characterized by numerous,
widely distributed red-yellow to red-brown xanthomatous
deposits aﬀecting the skin and mucosa in the absence of
hyperlipidemia [1]. Although the natural history of the
disease itself is usually benign, lesions in critical anatomical
locations may result in signiﬁcant morbidity and mortality
[2, 3]. XD characteristically involves the ﬂexural regions of
theskinandmucousmembranes;typically,theupperaerodi-
gestivemucusaisinvolved[4, 5].Systemicinvolvementisnot
uncommon, and lesions have been described in almost every
o r g a ns y s t e mi nt h eb o d y[ 1, 6]. Among them, skeletal, bone
marrow, hepatic, respiratory, ocular, and central nervous
system involvement are most common [7].
As an extremely rare condition, XD has only been
reported in roughly 100 patients, since it was ﬁrst deﬁned
by Montgomery and Osterberg in 1938 [8]. It can occur in
either sex and at any age, but it most commonly aﬀects male
childrenand young male adults[5,9]. Notypicalinheritance
pattern has previously been described, [10]n o rh a sX De v e r
beenassociated with any otherconditionsaspart ofa genetic
syndrome. We report, for the ﬁrst time, two cases of XD in a
pair of twin brothers, who developed blindness and deafness
in the ﬁrst decade of life.
2.Case Report
The patients are twin males who were born after a normal
pregnancy with no known maternal exposure to drugs or
viral infection. The authors do not declare whether the twins
are genetically identical or not. Their medical histories and
presentations were nearly identical and were signiﬁcant for
idiopathic, gradual loss of vision and hearing during early
childhood. Both brothers developed complete blindness and
deafness within the ﬁrst decade of life. The brothers’ two
sisters and their children are free of both cutaneous and
audiovisual abnormalities.
Onexamination, bothpatientshadmultiplefaciallesions
characterized by smooth, gelatinous-appearing papules,
some of which coalesced into large plaques. There were
also numerous small erythematous papules on the buttocks
regions. The upper extremities were uninvolved, but the
lower extremities had scattered well-deﬁned red or red-
brown papules that were waxy and densely clustered with
coalescing patches (Figure 1). There were also areas of mot-
tled hypopigmentation bilaterally on both patients’ lower2 ISRN Dermatology
Figure 1: Lesions of xanthoma disseminatum on the leg revealing
characteristic red-brown waxy lesions.
Figure 2: A biopsy section of the skin showing a diﬀuse histiocytic
inﬁltrate with foamy cytoplasm and Touton giant cells.
extremities, particularly focused in the knee and popliteal
regions.
On review of systems, the patients denied arthritis,
fatigue, weight loss, abdominal pain, bone pain, shortness of
breath, fevers, or chills.
A biopsy of each patient’s knees showed a histiocytic cel-
lularproliferationwithplasmacellsandmultinucleatedgiant
cells (Figure 2). The diﬀerential diagnosis included both
reactive and nonreactive causes of histiocytoses. Reactive
causes considered were lesions secondary to leishmaniasis,
syphilis, or atypical mycobacterial infection. Nonreactive
causes included Rasai-Dorfman disease, xanthoma dissem-
inatum, or Langerhans cell histiocytosis.
Doxycyclinewasempiricallystarted at100mgtwiceaday
to cover an atypical mycobacterial infection. Interestingly,
one twin patient developed a self-limited gyrate erythema
over his right ﬂank only two weeks after starting therapy.
During the course of his antibiotic treatment, it appeared
that established lesions improved; however, numerous new
lesions cropped up on his ﬂanks and dorsal feet in a
symmetric distribution. After 6 weeks of therapy, the patient
discontinued the doxycycline.
(a)
(b)
(c)
Figure 3: (a)Immunohistochemicallabeling ofthe biopsyshowing
CD1a negativity. (b) Immunohistochemical labeling of the biopsy
showing S100 negativity. (c) Immunohistochemical labeling of the
biopsy CD68 positivity.
Complete blood count, basic metabolic panel, and
thyroid and liver function tests were within normal limits.
Lipid panel revealed low serum triglycerides, normal
cholesterol levels and LDL with low HDL. Antinuclear
antibodies (ANA) and rapid plasma regain (RPR) were
negative. Urine histoplasma antigen was also negative.ISRN Dermatology 3
Immunohistochemical studies were performed to char-
acterize the nature of the inﬂammatory inﬁltrate (Figure 3).
The CD45, S-100, and CD1a stains were all negative,
indicating that the cells were neither lymphocytes nor
Langerhans cells. The CD68 stain was strongly positive,
revealing the presence of numerous macrophages. The fascin
stain was also positive, conﬁrming that the cells were
mature dendritic cells. These studies, in conjunction with
the clinical presentation, favored a diagnosis of xanthoma
disseminatum, and subsequently both twins were started on
a trial of methotrexate therapy at 15mg/wk.
To look for systemic involvement, several CT scans with
contrast were performed. The patients were found to have
a normal head, neck, heart, lungs, gallbladder, liver, spleen,
pancreas, adrenal glands, and kidneys. No retroperitoneal
lymphadenopathy was demonstrated.
3.Discussion
Xanthoma disseminatum is a rare xanthomatosis belonging
to a group of conditions known as the non-X histiocytoses.
It is characterized by xanthomatous deposits throughout the
body, particularly the ﬂexural areas of the skin. Involvement
is usually widespread and may become disﬁguring. In con-
trast to other xanthomatoses, it is classically normolipemic
[10, 11].
Xanthoma disseminatum was ﬁrst described in 1869 by
Von Grafe [12] butwasnot classiﬁedasa distinctentityuntil
1938 by Montgomery and Osterberg [8]. It was originally
thought to overlap with other Langerhans cell histiocytoses,
such as Hand-Schuller-Christian disease [2, 13]. However,
advanced immunochemical staining techniques have since
shown that it is clearly distinct from the Langerhans cell
histiopathies. The histologicaldemonstration ofCD1a,S100,
and Birbeck granules that is seen with Langherhans cell
histiopathiesis notseeninxanthoma disseminatum, [14–16]
which instead expresses CD68 positivity and Touton giant
cells, representing an exaggerated xanthomatoid reaction
[17].
The diagnosis of xanthoma disseminatum is based on
both clinical and pathological evidence. Clinical manifesta-
tions involving the skin, CNS, and respiratory tract are con-
sistent with the diagnosis, which can be conﬁrmed by biopsy
with immunophenotyping and ultrastructural studies [18].
Although the disease is generally benign, there have been
complicationsassociatedwiththeanatomicallocationsofthe
lesions. Xanthomatous lesions may not all be readily visible
to the naked eye. Involvement of aﬀected organs can be
demonstrated by imaging via X-ray, CT, MRI, ultrasound, or
ERCP. Approximately 40% of patients have mucocutaneous
involvement of the upper digestive and respiratory tracts,
resulting in hoarseness, dyspnea, and dysphagia [19]. This
can cause life-threatening obstruction and asphyxiation,
requiring tracheostomy [5, 19–22]. Extensive meningeal
involvement in the region of the sella and hypophysis is
t h o u g h tt ob et h ec a u s eo ft h ef r e q u e n ta s s o c i a t i o nw i t h
diabetes insipidus [3, 23–25]. Meningeal involvement may
also lead to seizures, ataxia, ophthalmoplegia, and growth
retardation [20, 26–29].
T h e r eh a v eb e e nf e wa d v a n c e m e n t sm a d ei nt h ed e v e l -
opment of a successful therapy for XD over the last decade.
Most popular methods of treatment include a combination
of chemotherapy, Cloﬁbrate, radiotherapy, surgery, and
steroidtreatment[18].Earlytreatmentofaggressivesubtypes
of XD with chemotherapy drugs such as Cyclophosphamide,
have notably better prognoses [30].
In our case, because no disease inﬁltration was seen on
CT, it is unlikely that this was the cause of the patients’
blindness and deafness. It is striking, however, that the
brothers share both cutaneous and audiovisual symptoms,
suggesting an association between the two.
Given the rarity of xanthoma disseminatum, with just
over100cases reported in the literature,the majority ofwhat
is known about the disease and its pathogenesis comes from
case reports. No typical inheritance pattern has previously
beendescribedinthesereports norhasiteverbeendescribed
as part of a genetic syndrome. This case of blind, deaf twin
brothers, both with xanthoma disseminatum, is the ﬁrst of
its kind and suggests that there may be geneticcomponent to
this condition. Furthermore, these cases suggest that in some
instances, XD might be associated with loss of hearing and
vision which are inherited as part of a genetic syndrome.
The association of hearing loss and cutaneous abnor-
malities has been previously described in a variety of
mammals [31]. In humans, Waardenburg syndrome is a
rare (1/40,000) autosomal dominant disorder characterized
by pigmentation defects and sensorineural deafness, and
eye abnormalities caused by the absence of melanocytes
in the skin and the stria vascularis of the inner ear.
Warburg Thomsen syndrome is an extremely rare condition
characterized by cutaneous hypomelanotic and pigmented
spots, microcornea, coloboma, and severe hearing loss.
These cases likely represent a new, neurocutaneous
genetic syndrome characterized by xanthomatous lesions,
hearing, and vision loss. Thus, xanthoma disseminatum
should be considered inthe workup ofa patientwith hearing
or vision loss who presents with cutaneous papules.
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